Over 200 GLP1 obesity programs are in development today.  More than 300 PD1/PDL1 cancer programs exist.  Greater than 150 programs target each of CD19 and KRAS. Therapeutic crowding has ratcheted up the competitive intensity in biotech to new levels. While

By Ankit Mahadevia, former CEO of Spero Therapeutics and Atlas alumni, as part of the From The Trenches of LifeSciVC I recently read Yuval Noah Hariri’s Nexus; what stuck with me was how a society uses information to create shared

By Cody Tranbarger, EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC It’s an interesting time to be thinking about space. Just a few months ago, SpaceX captivated and inspired the world by catching a

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Drug discovery and development is a long, and often fraught, journey – it typically takes more than a decade to progress from idea

The equity markets have collapsed in 2025, the IPO window is closed, the FDA is in turmoil, the NIH is being gutted… and it’s a great time to start new biotech companies. Why?  Because there are so few being created

By Jason Campagna, CMO of Q32 Bio, as part of the From The Trenches feature of LifeSciVC We’re entering a phase shift in biotech—one that extends beyond molecules, pipelines, or even platforms. Tariff escalations, supply chain fractures, and a reassertion

“When the going gets tough, the tough get going” By Ram Aiyar, CEO of Korro Bio, as part of the From the Trenches feature of LifeSciVC. It has been quite a start to the 2025 year. The sentiment around biotech

By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC Given everything going on in our world right now, I’ve been thinking a lot about the state of biotech innovation…particularly as we wrestle

By Ankit Mahadevia, serial biotech entrepreneur and former CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC I recently had an illuminating discussion with a seed-stage biotech Founder, who was reflecting after a hard and

By Cody Tranbarger, EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC For decades, muscular dystrophy has stubbornly persisted among the most intractable categories of human disease. Despite recent progress with AAV Gene Therapy and

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC In the perpetual and never-ending race by the healthcare sector to unearth new approaches and therapeutics to address disease, one area in which

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC “It was the best of times, it was the worst of times…” Another JPM is behind us, and while much of the small